Gossamer Bio Inc stock (US38198T1034): class action lawsuits follow PROSERA Phase 3 setback

Gossamer Bio faces multiple securities class action lawsuits after disclosing that its Phase 3 PROSERA trial in pulmonary hypertension failed to meet its primary endpoint, triggering a sharp share price drop and raising new questions about its pipeline and disclosures.

Gossamer Bio Inc is under legal and investor scrutiny after plaintiff law firms announced several securities class action lawsuits tied to the failure of its Phase 3 PROSERA trial and the resulting collapse in the company’s share price, according to releases from Hagens Berman on May 13, 2026 and Faruqi & Faruqi on May 13, 2026.Newsfile as of 05/13/2026PR Newswire as of 05/13/2026

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Gossamer Bio, Inc.
• Sector/industry: Biotechnology, biopharmaceuticals
• Headquarters/country: San Diego, United States
• Core markets: Pulmonary arterial hypertension and inflammatory diseases
• Key revenue drivers: Drug development pipeline and potential future product approvals
• Home exchange/listing venue: Nasdaq (ticker: GOSS)
• Trading currency: USD

Trigger: PROSERA miss and subsequent class action filings

The current wave of legal actions follows Gossamer Bio’s disclosure on February 23, 2026 that its Phase 3 PROSERA study in pulmonary hypertension did not meet its primary endpoint, a result that was accompanied by an approximately 80% drop in the company’s share price, according to a notice by Hagens Berman dated May 13, 2026.Newsfile as of 05/13/2026

The complaint highlighted by Hagens Berman alleges that Gossamer or its executives knew of, or recklessly disregarded, trial design issues with the PROSERA study while maintaining a narrative suggesting that the trial was on track to meet its main goal, according to the same May 13, 2026 release.Newsfile as of 05/13/2026

In parallel, other plaintiff firms including Glancy Prongay & Murray and Faruqi & Faruqi announced that investors who bought Gossamer shares during the alleged class period and suffered losses can seek to be appointed as lead plaintiff in the litigation, with one filing citing a lead plaintiff deadline of June 1, 2026, according to press releases dated May 13, 2026 and May 14, 2026.PR Newswire via Barchart as of 05/13/2026GlobeNewswire as of 05/14/2026

Gossamer Bio Inc: core business model

Gossamer Bio positions itself as a clinical-stage biopharmaceutical company focused on developing therapies for unmet needs in immunology, inflammation and pulmonary arterial hypertension. The company’s value proposition for shareholders is primarily tied to the development and potential commercialization of its pipeline assets rather than to existing product revenues.

As a clinical-stage player, Gossamer’s strategy typically involves advancing candidates through early and mid-stage clinical trials, generating proof-of-concept data, and pursuing larger registrational studies that, if positive, could support regulatory submissions in the United States and other markets. Success in such trials can materially influence the company’s ability to secure partnerships, raise capital, or eventually market approved therapies.

Gossamer’s operations rely heavily on external financing, as is common for biotech companies without approved drugs. This includes equity raises on Nasdaq, potential debt instruments, and partnerships or licensing agreements where larger pharmaceutical companies might provide upfront payments, milestone-based funding, or profit-sharing arrangements in exchange for rights to promising molecules.

The business model also depends on careful portfolio management, as the costs of late-stage clinical trials can be substantial. Decisions about which programs to prioritize or discontinue are therefore central to capital allocation and can significantly impact investor expectations, especially when a lead asset reaches or fails a pivotal Phase 3 study.

Main revenue and product drivers for Gossamer Bio Inc

Because Gossamer Bio does not yet market an approved blockbuster therapy, its current and prospective revenue streams are linked to its development pipeline and to any collaborations it may establish with larger pharmaceutical partners. The most advanced assets can act as the main value drivers, especially when they address serious diseases with limited treatment options such as pulmonary arterial hypertension.

The PROSERA Phase 3 trial was a key part of this strategy, aiming to demonstrate efficacy and safety in a pulmonary hypertension population. A successful outcome might have paved the way for a regulatory filing and, over time, product revenue. The disclosed failure to meet the primary endpoint in PROSERA has therefore been a major setback for this particular revenue pathway, according to the law firm notices that reference the February 23, 2026 update.PR Newswire as of 05/13/2026

Beyond PROSERA, Gossamer typically seeks to diversify risk across several programs in immunology and inflammation, so that the failure of one trial does not entirely negate the company’s long-term prospects. Early-stage or mid-stage studies can yield data that attracts strategic interest from larger pharmaceutical players, potentially generating licensing income or collaboration revenue even before any product reaches the market.

However, such revenues are uncertain and contingent on scientific and clinical success, regulatory outcomes, and the negotiating power of the company at the time of partnership discussions. As a result, investor sentiment around Gossamer tends to react strongly to trial readouts, safety updates, and guidance on development timelines, all of which can change expectations around future cash flows.

Legal allegations and key elements of the class actions

The securities class action described by Hagens Berman alleges that, during the proposed class period, Gossamer and certain executives made materially false or misleading statements and failed to disclose trial design issues with the PROSERA Phase 3 study. According to that May 13, 2026 notice, the complaint contends that investors were led to believe the trial would meet its primary endpoint, which did not occur when topline data were announced on February 23, 2026.Newsfile as of 05/13/2026

Other law firms, including Glancy Prongay & Murray and Faruqi & Faruqi, describe similar alleged misconduct, citing potential violations of federal securities laws and inviting investors who purchased Gossamer shares within a specified period to join the cases. These notices often highlight that plaintiffs seek to recover damages for losses incurred when the stock price fell sharply after the PROSERA results were disclosed, according to releases dated May 13, 2026.Morningstar/PR Newswire as of 05/13/2026

The Faruqi & Faruqi update notes a class period running from June 16, 2025 through February 20, 2026 and emphasizes a lead plaintiff deadline of June 1, 2026, signaling that the early procedural steps in the litigation are currently underway, according to its May 13, 2026 communication.PR Newswire as of 05/13/2026

At this stage, the complaints represent allegations rather than findings of liability. The outcomes will depend on court decisions regarding motions to dismiss, class certification, discovery, and potential settlement discussions. Such processes can take years, and the ultimate financial impact on Gossamer Bio, if any, remains uncertain.

Share price reaction and market context for US investors

Law firm notices emphasize that Gossamer’s share price declined by around 80% in response to the February 23, 2026 announcement of adverse topline results from the PROSERA study, though precise intraday levels and closing prices vary by data provider, according to the Hagens Berman release from May 13, 2026.Newsfile as of 05/13/2026

On the Nasdaq, where Gossamer trades under the ticker GOSS, such a move represents a significant destruction of market capitalization and shifts the company’s perceived risk profile. US-based biotech investors often face similar binary outcomes linked to pivotal trial readouts, where success can unlock substantial value and failure can raise questions about funding and strategic options.

In the broader US biotech sector, companies focused on rare diseases and pulmonary arterial hypertension compete for specialist investor attention. Gossamer’s PROSERA setback therefore has implications not only for its own valuation but also for how investors assess late-stage trial risk, communication practices, and the robustness of trial designs that underpin investment cases.

Why Gossamer Bio Inc matters for US investors

For US investors, Gossamer Bio represents an example of the high-risk, high-uncertainty profile associated with clinical-stage biotechnology companies listed on domestic exchanges. The company is part of a cohort of emerging pharma players seeking to address serious diseases and, if successful, to generate substantial future cash flows from innovative therapies.

Because Gossamer is listed on Nasdaq and reports in US dollars, it is directly accessible to many US retail and institutional investors without currency conversion complexities. Changes in its share price, litigation status, or development pipeline can feed into biotech index performance and sentiment, particularly among funds focused on small- and mid-cap life sciences names in the United States.

In addition, regulatory and legal developments around Gossamer’s disclosures may be watched by other US-listed biotech firms as a reference point for how communications about trial design, endpoints, and expectations are scrutinized in the context of securities laws. This dynamic can influence disclosure practices across the sector.

Conclusion

Gossamer Bio Inc is navigating a challenging period marked by the failure of its Phase 3 PROSERA study and the resulting securities class action lawsuits that allege misleading disclosures. As a clinical-stage biotech, the company’s prospects continue to depend heavily on its remaining pipeline and its ability to secure funding and partnerships in the wake of this setback. For US investors focused on biotech, the case highlights the importance of trial design, communications, and binary outcome risk, while the ultimate impact of the litigation and strategic responses will likely unfold over an extended time frame.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.